The long-term efficacy and safety of new biological therapies for psoriasis

Por Papp, Kim A.
Publicado em 2006

The safety of etanercept for the treatment of plaque psoriasis

Por Papp, Kim A
Publicado em 2007

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast

Por Gooderham, Melinda, Papp, Kim
Publicado no BioDrugs (2015)

Evaluation of efalizumab using safe psoriasis control

Por Papp, Kim A, Henninger, Eric
Publicado em 2006

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

Por Papp, Kim A, Toth, Darryl, Rosoph, Les
Publicado em 2006

Secukinumab: Review of Clinical Evidence from the Pivotal Studies ERASURE, FIXTURE, and CLEAR

Por Armstrong, April W., Papp, Kim, Kircik, Leon
Publicado no J Clin Aesthet Dermatol (2016)

A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris

Por Taraska, Victoria, Tuppal, Raj, Olesen, Martin, Bang Pedersen, Claus, Papp, Kim
Publicado no J Cutan Med Surg (2016)

Immunosuppressive therapy in dermatology and PML

Por Sterry, Wolfram, Bagot, Martine, Ferrandiz, Carlos, Kragballe, Knud, Papp, Kim, Stingl, Georg
Publicado em 2009

Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Con...

Por Papp, Kim A., Armstrong, April W., Reich, Kristian, Karunaratne, Mahinda, Valdecantos, Wendell
Publicado no Am J Clin Dermatol (2015)

Approaches to reporting long-term data

Por Papp, Kim A., Fonjallaz, Philippe, Casset-Semanaz, Florence, Krueger, James G., Wittkowski, Knut M.
Publicado em 2008

Evaluating practice patterns for managing moderate to severe plaque psoriasis: Role of the family physician

Por Poulin, Yves, Wasel, Norman, Chan, Daphne, Bernstein, Geula, Andrew, Robin, Fraquelli, Elisa, Papp, Kim
Publicado em 2012

Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis

Por Anil Kumar, Mysore S., Papp, Kim, Tainaka, Ryo, Valluri, Udaya, Wang, Xuegong, Zhu, Tong, Schwabe, Christian
Publicado no Biopharm Drug Dispos (2018)

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomi...

Por Strand, Vibeke, Fiorentino, David, Hu, ChiaChi, Day, Robert M, Stevens, Randall M, Papp, Kim A
Publicado em 2013

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series

Por Lowes, Michelle A, Chamian, Francesca, Abello, Maria V, Leonardi, Craig, Dummer, Wolfgang, Papp, Kim, Krueger, James G
Publicado em 2007

Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis

Por Valenzuela, Fernando, Papp, Kim A, Pariser, David, Tyring, Stephen K, Wolk, Robert, Buonanno, Marjorie, Wang, Jeff, Tan, Huaming, Valdez, Hernan
Publicado no BMC Dermatol (2015)

Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome

Por Lima, Hermenio, Gooderham, Melinda, Dutz, Jan, Lynde, Charles, Chapdelaine, Hugo, Ellis, Anne, Gilbert, Martin, Ho, Vincent, Papp, Kim, Poulin, Yves, Sussman, Gordon
Publicado no Allergy Asthma Clin Immunol (2017)

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNC...

Por Blauvelt, Andrew, Papp, Kim A., Griffiths, Christopher E. M., Puig, Luis, Weisman, Jamie, Dutronc, Yves, Kerr, Lisa Farmer, Ilo, Dapo, Mallbris, Lotus, Augustin, Matthias
Publicado no Am J Clin Dermatol (2017)

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque...

Por Blauvelt, Andrew, Papp, Kim A., Griffiths, Christopher E. M., Puig, Luis, Weisman, Jamie, Dutronc, Yves, Kerr, Lisa Farmer, Ilo, Dapo, Mallbris, Lotus, Augustin, Matthias
Publicado no Am J Clin Dermatol (2018)

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

Por Papp, Kim A., Bissonnette, Robert, Gooderham, Melinda, Feldman, Steven R., Iversen, Lars, Soung, Jennifer, Draelos, Zoe, Mamolo, Carla, Purohit, Vivek, Wang, Cunshan, Ports, William C.
Publicado no BMC Dermatol (2016)

Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo‐controlled phase 3 trial

Por Abe, Masatoshi, Nishigori, Chikako, Torii, Hideshi, Ihn, Hironobu, Ito, Kei, Nagaoka, Makoto, Isogawa, Naoki, Kawaguchi, Isao, Tomochika, Yukiko, Kobayashi, Mihoko, Tallman, Anna M., Papp, Kim A.
Publicado no J Dermatol (2017)